Genentech Receives FDA Approval of Evrysdi (risdiplam) for the Treatment of SMA

Leave a Comment / Front Page News, Research /

Genentech, a member of the Roche Group, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Evrysdi (risdiplam) to treat adults and children 2 months and older with spinal muscular atrophy (SMA). Evrysdi showed clinically meaningful improvements in motor function across two clinical trials in people with varying ages and levels […]

Genentech Receives FDA Approval of Evrysdi (risdiplam) for the Treatment of SMA Read More »

Cure SMA Launches New Medical Alert Bracelet Support Program

2 Comments / Front Page News, Support & Care /

Along with funding SMA research and care, Cure SMA provides thousands of individuals and families with vital support and resources that help people navigate life with spinal muscular atrophy (SMA). In addition to our current support programs, Cure SMA is thrilled to launch a brand-new program offered to all affected individuals with SMA to help

Cure SMA Launches New Medical Alert Bracelet Support Program Read More »

Cure SMA to Meet with FDA for Critical Path Innovation Meeting

1 Comment / Front Page News, Support & Care /

We are excited to share with the SMA community that the U.S. Food and Drug Administration (FDA) has granted Cure SMA a Critical Path Innovation Meeting (CPIM). This means that key leaders at the FDA will have the opportunity to communicate with clinical investigators, members of academia, industry, scientific groups, and patients to improve efficiency

Cure SMA to Meet with FDA for Critical Path Innovation Meeting Read More »

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma

Leave a Comment / Clinical Trials, Front Page News /

Biogen Inc., today announced, it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma (onasemnogene abeparvovec). People with SMA do not produce enough survival

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma Read More »

Community Spotlight: Avery’s Diagnosis from Newborn Screening

Leave a Comment / Community Spotlight /

July 2020 marks the 2-year anniversary of when the U.S. Secretary of Health and Human Services recommended that SMA be added to state newborn screening panels. This month, you’ll hear about newborn screening milestones, stories, and steps you can take to ensure all states screen newborns for SMA. Shannon’s story of her family’s experience with

Community Spotlight: Avery’s Diagnosis from Newborn Screening Read More »

Thank You for a Wonderful 2020 Virtual SMA Conference!

3 Comments / Conference, Front Page News /

Cure SMA would like to thank everyone who attended last week’s 2020 Virtual SMA Conference! It was an impactful week of online workshops, networking, and community. We are happy to announce that there were more than 6,600 participants who attended the 28 offered live events. Although we were unable to come together in-person, it was

Thank You for a Wonderful 2020 Virtual SMA Conference! Read More »

Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults with SMA

1 Comment / Conference, Research /

      Genentech, a member of the Roche Group, shared two-year data from Part 1 of its pivotal SUNFISH trial in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). This was presented at the 2020 Virtual SMA Research & Clinical Care Meeting. The results of an exploratory efficacy analysis

Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults with SMA Read More »

Biogen Shares Results from Landmark NURTURE Study of Pre-Symptomatic SMA Patients Treated with Spinraza

1 Comment / Conference, Research /

      Biogen, Inc., today announced new results from NURTURE, the longest study of pre-symptomatic patients with spinal muscular atrophy (SMA), which is transforming expectations of early treatment with SPINRAZA (nusinersen). In infants genetically diagnosed with SMA, new data demonstrate that early and sustained treatment with SPINRAZA for up to 4.8 years enabled unprecedented

Biogen Shares Results from Landmark NURTURE Study of Pre-Symptomatic SMA Patients Treated with Spinraza Read More »

2020 Virtual SMA Conference Booklet is Now Available Online

Leave a Comment / Conference, Front Page News /

Cure SMA is pleased to announce that the 2020 Virtual SMA Conference booklet is now available for download. The booklet includes important details on the Virtual SMA Conference, including: A full agenda with event descriptions and speaker bios for the 16 virtual topical workshops. Don’t forget to register for each individual event that you are

2020 Virtual SMA Conference Booklet is Now Available Online Read More »

Scroll to Top